EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review

Shivani Patel, Heather Armbruster, Gretchen Pardo, Brianna Archambeau, Na Hyun Kim, Joanne Jeter, Richard Wu, Kari Kendra, Carlo M Contreras, Natalie Spaccarelli, Brittany Dulmage, Llana Pootrakul iD und 2 weitere

PLOS ONE · 30.04.2024 · 19 (4) · e0297531

DOI: 10.1371/journal.pone.0297531 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 30.04.2024. Verfasst von Shivani Patel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The James Cancer Hospital, Columbus, OH, United States of America. Hauptthemen laut MEDLINE: Basal Cell Carcinoma, Pyridines, Anilides, Hedgehog Proteins. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Basal cell carcinoma (BCC) is highly curable by surgical excision or radiation. In rare cases, BCC can be locally destructive or difficult to surgically remove. Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. This retrospective chart review also investigates the impact of CoQ10 and calcium supplementation in patients treated with HHI drugs at a single academic medical center from 2012 to 2022. We reviewed the charts of adult patients diagnosed with locally advanced or metastatic BCC treated with vismodegib or sonidegib primarily for progression-free survival (PFS). Secondary objectives included overall survival, BCC-specific survival, time to and reasons for discontinuation, overall response rate, safety and tolerability, use of CoQ10 and calcium supplements, and insurance coverage. Of 55 patients assessable for outcome, 34 (61.8%) had an overall clinical benefit, with 25 (45.4%) having a complete response and 9 (16.3%) a partial response. Stable disease was seen in 14 (25.4%) and 7 (12.7%) progressed. Of the 34 patients who responded to treatment, 9 recurred. Patients who were rechallenged with HHI could respond again. The median overall BCC-specific survival rate at 5 years is 89%. Dose reductions or discontinuations for vismodegib and sonidegib occurred in 59% versus 24% of cases, or 30% versus 9% of cases, respectively. With CoQ10 and calcium supplementation, only 17% required a dose reduction versus 42% without. HHI is highly effective for treating advanced BCC but may require dosing decreases. Sonidegib was better tolerated than vismodegib. CoQ10 and calcium supplementation can effectively prevent muscle spasms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Basal Cell CarcinomaPyridinesAnilidesHedgehog ProteinsHumansRetrospective StudiesMaleFemaleMiddle AgedAgedSkin NeoplasmsBiphenyl CompoundsAdultUbiquinoneAged, 80 and overNeoplasm Metastasis

Substanzen

PyridinesAnilidesHhAntag691Hedgehog ProteinssonidegibBiphenyl CompoundsUbiquinonecoenzyme Q10

Autor:innen und Institutionen

  • Department of Pharmacy, The James Cancer Hospital, Columbus, OH, United States of America.
  • Celltrion, Incheon, South Korea.
  • Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States of America.
  • Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States of America.
  • Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, Unites States of America.
  • Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, OH, Unites States of America.

ORCID-Profile: Llana Pootrakul

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Patel, S., Armbruster, H., Pardo, G., Archambeau, B., Kim, N. H., Jeter, J., Wu, R., Kendra, K., Contreras, C. M., Spaccarelli, N., Dulmage, B., Pootrakul, L., Carr, D. R., & Verschraegen, C. (2024). Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review. PLOS ONE, 19(4), e0297531. https://doi.org/10.1371/journal.pone.0297531

Vancouver

Patel S, Armbruster H, Pardo G, Archambeau B, Kim NH, Jeter J, et al. Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review. PLOS ONE. 2024;19(4):e0297531. doi:10.1371/journal.pone.0297531

BibTeX
@article{Patel2024,
  author = {Patel, Shivani and Armbruster, Heather and Pardo, Gretchen and Archambeau, Brianna and Kim, Na Hyun and Jeter, Joanne and Wu, Richard and Kendra, Kari and Contreras, Carlo M and Spaccarelli, Natalie and Dulmage, Brittany and Pootrakul, Llana and Carr, David R and Verschraegen, Claire},
  title = {Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {4},
  pages = {e0297531},
  doi = {10.1371/journal.pone.0297531}
}
Kostenlos starten →